{{--
  Back to User
--}}
{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode'])) Logout @endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
Back

A survey of practice patterns & treatment choices of neuroprotectants in the management of acute stroke

Survey Questionnaire Form
Doctor’s details
@if(isset(session()->get('doctor')['vCentralCode']))
@else
@endif

Questionnaire

  1. How many patients of acute stroke do you see in a month?*

  2. From your clinical experience, mention the most common symptoms patients present to you at diagnosis? *
  3. Do you consider neuroprotectants as a first-line treatment for acute stroke? *

  4. Mention the Neuroprotectants being used in your clinical practice? *
  5. What percentage of your acute stroke patients achieve satisfactory symptom relief with neuroprotectants alone? *

  6. In your practice, what proportion of acute stroke patients require neuroprotectants in combination with initial therapy? *

  7. What percentage of your acute stroke patients are currently prescribed neuroprotectants? *

  8. In your experience, how effective do you find neuroprotectants in managing acute stroke symptoms? *
  9. On a scale of 1 to 5, How satisfied are you with the current dosing options available for neuroprotectants? (5 being very satisfied) *

  10. Which dosage options are you prescribing/using the most for Citicoline? *

  11. What is your typical starting dose of Citicoline injection in acute stroke patients? *

  12. In your experience, how quickly do patients typically respond to Citicoline treatment? *

  13. Which factors are critical for choosing Citicoline in managing acute stroke? *
  14. How often do you adjust the dosage of Citicoline for optimal symptom management? *

  15. On average, how long do your patients remain on Citicoline treatment post discharge? *

  16. In your experience, does Citicoline provide long-term benefits for acute stroke patients? *

  17. Have you observed any differences in treatment response based on patient’s age when prescribing neuroprotectants in acute stroke patients? *

  18. Have you observed any differences in treatment response based on patient’s gender when prescribing neuroprotectants in acute stroke patients? *

  19. What percentage of your patients report satisfactory compliance with Citicoline treatment? *

  20. How do you typically monitor the effectiveness of neuroprotectants treatment in your patients? *
  21. How satisfied are your patients with the response of the Citicoline in managing acute stroke? (5 being very satisfied) *

  22. How satisfied are your patients with the tolerability of Citicoline in managing acute stroke? (5 being very satisfied) *

  23. What percentage of your acute stroke patients receive Citicoline within the recommended time frame? *

  24. Do you find neuroprotectants more effective than other medications commonly prescribed for acute stroke? *

  25. What percentage of patients are satisfied with tolerance to Citicoline?*

  26. How do you assess the long-term efficacy of neuroprotectants in managing acute stroke? *
  27. What percentage of your acute stroke patients experience significant improvement in quality of life with Citicoline? *

  28. How do you prioritize the use of Citicoline in the acute care setting? *
  29. What percentage of your patients with acute stroke have comorbidities that influence your decision to prescribe Citicoline? *

  30. Based on your experience, do you think additional research is needed to better understand neuroprotectants in acute stroke management? *

  31. In your opinion, what advantage does Citicoline offer over other neuroprotectants in acute stroke management? *
  32. How would you rate your overall experience with prescribing Citicoline in acute stroke management? (5 being very satisfied) *

  33. How do you adjust the treatment plan based on the disease progression? *